drugset / Trial / NCT03540524
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.
Timeline
- Start
- 2018-05-31
- Primary completion
- 2019-03-11
- Completion
- 2019-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLPG2451 | Unknown | — | Oral |
| Subject | GLPG2737 | Small molecule | — | Oral |
| Subject | Galicaftor | Small molecule | — | Oral |